About The Study: In this economic evaluation, undergoing risk-reducing mastectomy (RRM) appears cost-effective for women ages 30 to 55 with a lifetime breast cancer risk of 35% or higher. These results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers. Future studies evaluating the acceptability, uptake, and long-term outcomes of RRM among these women are warranted.
Corresponding Author: To contact the corresponding author, Ranjit Manchanda, MD, PhD, email r.manchanda@qmul.ac.uk .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2025.2203)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2025.2203?guestAccessKey=cdb465a6-c7a9-4b2b-b96c-ccafe41f4d03&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=072425
JAMA Oncology